Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a ...

Premature infants (delivery before 37 wk of gestation) admitted to the NICU at the University of Iowa Children's Hospital between 2000 and 2009 were recruited to examine preterm birth (PTB) and ...

Atlanta seems ready to move on from the Trae Young era. Which teams make realistic trade partners — and which ones don't?

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

An updated strategy for the technical security of the public sector includes initiatives such as the creation of new ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

As China’s technological and military power continues to grow, the central issue is whether Beijing can accommodate a stable ...

Tradewinds Universal, Inc. (OTCID: TRWD), a fully reporting publicly traded holding company, today outlined its initial 2026 ...